COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS

被引：0
|
作者：
Sabater, E. [1 ]
Rueda, A. [2 ]
Salar, A. [3 ]
Lopez-Guillermo, A. [4 ]
Oyagueez, I. [1 ]
Collar, J. M. [5 ]
机构：
[1] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[2] Hosp Costa del Sol, Dept Oncol, Marbella, Spain
[3] Hosp del Mar, Hematol Dept, Madrid, Spain
[4] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[5] Mundipharma Pharmaceut, Dept Med, Madrid, Spain
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1270
引用
收藏
页码：487 / 488
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF RITUXIMAB IN FOLLICULAR LYMPHOMA FIRST LINE MAINTENANCE TREATMENT FROM PUBLIC PAYER PERSPECTIVE IN POLAND
    Gadaj, A.
    Kalinowska, A.
    Hawrylecka, D.
    Holojda, J.
    Krawcewicz, A.
    Spychalowicz, W.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A450
  • [32] COST-EFFECTIVENESS OF BENDAMUSTINE-RITUXIMAB IN FIRST-LINE INDOLENT NHL: A PATIENT-LEVEL SIMULATION
    Dewilde, S.
    Woods, B.
    Castaigne, J. G.
    Parker, C.
    Dunlop, W.
    VALUE IN HEALTH, 2013, 16 (07) : A415 - A415
  • [33] COMPARISON OF FIRST-LINE TREATMENT WITH BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP FOR PATIENTS WITH FOLLICULAR LYMPHOMA GRADE 3A: RESULTS OF AN ITALIAN MULTICENTER, RETROSPECTIVE STUDY
    Margiotta-Casaluci, G.
    Bigliardi, S.
    Cocito, F.
    Meli, E.
    Petrucci, L.
    Nicolosi, M.
    Annibali, O.
    Boccomini, C.
    Bozzola, V.
    Castellino, A.
    Cattina, F.
    Cenfra, N.
    Ciavarella, S.
    Kovalchuk, S.
    Rotondo, F.
    Fama, A.
    Olivieri, J.
    Zaja, F.
    HAEMATOLOGICA, 2021, 106 (10) : 91 - 91
  • [34] Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway
    Fredrik Salvesen Haukaas
    Audun Ohna
    Tania Krivasi
    Applied Health Economics and Health Policy, 2018, 16 : 569 - 577
  • [35] Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway
    Haukaas, Fredrik Salvesen
    Ohna, Audun
    Krivasi, Tania
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (04) : 569 - 577
  • [36] CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    Marcus, R
    Imrie, K
    Belch, A
    Cunningham, D
    Flores, E
    Catalano, J
    Solal-Celigny, P
    Offner, F
    Walewski, J
    Raposo, J
    Jack, A
    Smith, P
    BLOOD, 2005, 105 (04) : 1417 - 1423
  • [37] ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Lachaine, J.
    Kouroukis, C. T.
    VALUE IN HEALTH, 2016, 19 (03) : A248 - A248
  • [38] Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
    Zucca, Emanuele
    Rondeau, Stephanie
    Vanazzi, Anna
    Ostenstad, Bjorn
    Mey, Ulrich J. M.
    Rauch, Daniel
    Wahlin, Bjorn E.
    Hitz, Felicitas
    Hernberg, Micaela
    Johansson, Ann-Sofie
    Brown, Peter de Nully
    Hagberg, Hans
    Ferreri, Andres J. M.
    Lohri, Andreas
    Novak, Urban
    Zander, Thilo
    Bersvendsen, Hanne
    Bargetzi, Mario
    Mingrone, Walter
    Krasniqi, Fatime
    Dirnhofer, Stefan
    Hayoz, Stefanie
    Hawle, Hanne
    Vilei, Simona Berardi
    Ghielmini, Michele
    Kimby, Eva
    Caspar, Clemens
    Koberle, Dieter
    Novak, Urban
    Zenhausern, Reinhard
    Jost, Lorenz M.
    Mach, Nicolas
    Voegeli, Michele
    Tscherry, Georg
    Fischer, Natalie
    Burkhard, Roger
    Schmid, Mathias
    Panagiotis, Samaras
    Munksgaard, Lars
    Hernberg, Micaela
    Vasala, Kaija
    Lehtinen, Tuula
    Jyrkkio, Sirkku
    Ekanger, Roald
    Rolke, Jurgen
    Meyer, Peter
    Maisenholder, Martin
    Eidem, Monika
    Radlund, Anders
    Lagerlof, Ingemar
    BLOOD, 2019, 134 (04) : 353 - 362
  • [39] Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study
    Blommestein, Hedwig M.
    Issa, Djamila E.
    Pompen, Marjolein
    Revil, Cedric
    Hoogendoorn, Mels
    Joosten, Peter
    Zweegman, Sonja
    Huijgens, Peter C.
    Uyl-de Groot, Carin A.
    BLOOD, 2012, 120 (21)
  • [40] Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma
    De la Cruz Vicente, Fatima
    Carrillo-Cruz, Estrella
    Sole Rodriguez, Maria
    Marin Niebla, Ana
    Martino Galiana, Maria Luz
    Falantes Gonzalez, Jose
    Montero Cuadrado, Isabel
    Gonzalez Campos, Jose
    Espigado Tocino, Ildefonso
    Rios-Herranz, Eduardo
    Antonio Perez-Simon, Jose
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (06) : 469 - 475
12345